[go: up one dir, main page]

CA2260145A1 - Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 - Google Patents

Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1

Info

Publication number
CA2260145A1
CA2260145A1 CA002260145A CA2260145A CA2260145A1 CA 2260145 A1 CA2260145 A1 CA 2260145A1 CA 002260145 A CA002260145 A CA 002260145A CA 2260145 A CA2260145 A CA 2260145A CA 2260145 A1 CA2260145 A1 CA 2260145A1
Authority
CA
Canada
Prior art keywords
igf
acetylcarnitine
levels
increasing
isovalerylcarnitine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002260145A
Other languages
French (fr)
Other versions
CA2260145C (en
Inventor
Claudio De Simone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendes SRL
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11404324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2260145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2260145A1 publication Critical patent/CA2260145A1/en
Application granted granted Critical
Publication of CA2260145C publication Critical patent/CA2260145C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Use of L-acetylcarnitine, L-isovalerylcamitine, L-propionylcamitine or pharmacologically acceptable salts thereof for increasing the levels of IGF-1 for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1.
CA002260145A 1996-07-05 1997-05-15 Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 Expired - Fee Related CA2260145C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM96A000479 1996-07-05
IT96RM000479A IT1290801B1 (en) 1996-07-05 1996-07-05 USE OF ACETYL L-CARNITINE, ISOVALERYL L-CARNITINE, PROPIONYL L-CARNITINE OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS
PCT/IT1997/000113 WO1998001128A1 (en) 1996-07-05 1997-05-15 Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1

Publications (2)

Publication Number Publication Date
CA2260145A1 true CA2260145A1 (en) 1998-01-15
CA2260145C CA2260145C (en) 2007-01-09

Family

ID=11404324

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002260145A Expired - Fee Related CA2260145C (en) 1996-07-05 1997-05-15 Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1

Country Status (11)

Country Link
US (2) US6037373A (en)
EP (1) EP0909171B1 (en)
JP (1) JP2000514437A (en)
KR (1) KR100479669B1 (en)
AT (1) ATE273701T1 (en)
CA (1) CA2260145C (en)
DE (1) DE69730330T2 (en)
ES (1) ES2225968T3 (en)
IT (1) IT1290801B1 (en)
PT (1) PT909171E (en)
WO (1) WO1998001128A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1290801B1 (en) * 1996-07-05 1998-12-11 Mendes Srl USE OF ACETYL L-CARNITINE, ISOVALERYL L-CARNITINE, PROPIONYL L-CARNITINE OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS
US6380252B1 (en) * 1996-07-05 2002-04-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
IT1288399B1 (en) * 1996-12-03 1998-09-22 Sigma Tau Ind Farmaceuti MEDICATION FOR THE THERAPEUTIC TREATMENT OF AGE-RELATED MACULOPATHY, NON-AGE-RELATED MACULOPATHY AND FOR PROPHYLAXIS
DE19718826A1 (en) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Use of biologically active agents to influence the extracellular space of sensory cells and methods for drug administration control
IT1306178B1 (en) 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti USE OF L-CARNITINE AND ITS ALCANOIL DERIVATIVES FOR THE PREPARATION OF A USEFUL DRUG IN THE TREATMENT OF THE PATIENT WITH
IT1316990B1 (en) * 2000-02-17 2003-05-26 Sigma Tau Ind Farmaceuti METHOD TO INCREASE GENE EXPRESSION FOR TRANSFECTED GENES.
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
IT1317937B1 (en) * 2000-11-17 2003-07-15 Sigma Tau Healthscience Spa COMPOSITION TO STIMULATE IMMUNITY DEFENSES AND THE METABOLISM OF IRON INCLUDING AN ALCANOIL L-CARNITINA AND LATTOFERRINA.
IT1317938B1 (en) * 2000-11-17 2003-07-15 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF ALTERATIONS OF LIPID METABOLISM, OF ALLERGIC FORMS AND TO ACTIVATE DEFENSES
IT1317079B1 (en) * 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti USE OF ISOVALERIL L-CARNITINE FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS.
ITRM20010708A1 (en) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti USE OF AN ALCANOIL L-CARNITINE FOR THE TREATMENT OF ERECTILE DYSFUNCTION.
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20050106183A1 (en) * 2002-01-31 2005-05-19 Lamb Gregory B. Method of treating pain
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
ITRM20020492A1 (en) * 2002-10-01 2004-04-02 Sigma Tau Ind Farmaceuti USE OF PROPIONYL L-CARNITINE FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF GLAUCOMA.
ITRM20020620A1 (en) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti USE OF CARNITINE FOR THE PREVENTION AND / OR TREATMENT OF DISORDERS CAUSED BY ANDROPAUSE.
US7776913B2 (en) * 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause
ATE437884T1 (en) * 2003-05-29 2009-08-15 Jay W Pettegrew GLYCEROPHOSPHOCHOLINE AND DERIVATIVES THEREOF FOR THE MEDICAL IMAGING OF NEUROPSYCHIATRIC DISEASES
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
EP2194140A2 (en) 2005-03-02 2010-06-09 Metanomics GmbH Process for the production of fine chemicals
JP2006347935A (en) * 2005-06-15 2006-12-28 Masanori Ogata Pharmaceutical for preventing/treating disease related to inflammatory cytokine production
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
US7957213B2 (en) * 2006-02-09 2011-06-07 Hynix Semiconductor, Inc. Semiconductor memory apparatus
KR100738959B1 (en) 2006-02-09 2007-07-12 주식회사 하이닉스반도체 Sense Amplifier Power Supply Circuit and Method of Semiconductor Memory Device
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
EP2136798B1 (en) * 2007-03-21 2015-07-29 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
US20100099640A1 (en) * 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
AU2008253134A1 (en) * 2007-05-24 2008-11-27 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the prevention of adverse effect due to the use of PPAR-gamma agonists
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN117159528A (en) * 2023-01-13 2023-12-05 再造再生健康科技(杭州)有限公司 Compositions for promoting enhanced secretion of endogenous insulin-like growth factor 1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245699B (en) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti L-CARNITINE DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF MYOPATHIES, NEURONAL DEGENARATION AND TO INHIBIT PROTEOLYSIS
US5240961A (en) * 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
WO1995000137A1 (en) * 1993-06-21 1995-01-05 Bernardini, Attilio Use of acylcarnitin to treat illnesses caused by aids
IT1290801B1 (en) * 1996-07-05 1998-12-11 Mendes Srl USE OF ACETYL L-CARNITINE, ISOVALERYL L-CARNITINE, PROPIONYL L-CARNITINE OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS

Also Published As

Publication number Publication date
KR20000022515A (en) 2000-04-25
EP0909171B1 (en) 2004-08-18
DE69730330T2 (en) 2005-02-10
US6166077A (en) 2000-12-26
CA2260145C (en) 2007-01-09
KR100479669B1 (en) 2005-06-13
ES2225968T3 (en) 2005-03-16
ATE273701T1 (en) 2004-09-15
DE69730330D1 (en) 2004-09-23
EP0909171A1 (en) 1999-04-21
WO1998001128A1 (en) 1998-01-15
ITRM960479A0 (en) 1996-07-05
US6037373A (en) 2000-03-14
ITRM960479A1 (en) 1998-01-05
PT909171E (en) 2004-11-30
IT1290801B1 (en) 1998-12-11
JP2000514437A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
IL121170A0 (en) Compositions for the treatment of dermatological disorders
WO1998025930A3 (en) Use of bi- and tricyclic pyridone derivatives against alzheimer's disease
KR100246065B1 (en) Substituted 3-aminoquinuclidines
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
AU678795B2 (en) Application of riluzole in the treatment of neurological lesions related to traumatic injuries
CA2338220A1 (en) Substituted imidazoles having cytokine inhibitory activity
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
CA2199844A1 (en) Compositions for the treatment of skin disorders
CA2154103A1 (en) Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
CA2176298A1 (en) A single high dose fluoroquinolone treatment
AU1117092A (en) Treatment of lower urinary tract disorders
AU7833194A (en) Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
EP1440689A3 (en) Treatment of neurotic disorders
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
WO2000051582A3 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
CA2301706A1 (en) Use of phanquinone for the treatment of alzheimer's disease
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
CA2260863A1 (en) Treatment of psychotic disorders
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed